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ABSTRACT
Background: Dialysis patients experience multiple symptoms impairing their quality of life. A relationship seems to exist
between the cultural context and the burden of symptoms. In this study, the prevalence and severity of 30 symptoms and their
relationship with quality of life among hemodialysis patients in Switzerland is explored.
Methods: A cross-sectional correlation design was used with a convenience sample of 119 patients from five dialysis units.
Presence and severity of symptoms were assessed with the Dialysis Symptom Index and quality of life with the WHOQOL-Bref
questionnaire. Multivariate linear regressions were used to examine the relationship between the prevalence and severity of
symptoms, respectively, and quality of life. T-tests and Fisher’s tests were used for the international comparisons.
Results: On average, patients reported 10 symptoms and often rated these as “somewhat bothersome”. The most frequent were:
lack of energy, dry skin, trouble falling asleep, trouble staying asleep, and muscle cramps. Average symptoms prevalence and
severity levels were both observed to decrease patients’ quality of life, items related to physical health and psychological state
having the greatest impact. Prevalence and severity of psychological symptoms and prevalence of sex-related symptoms seem to
be influenced by patients’ cultural context.
Conclusions: These results demonstrate that patients on chronic hemodialysis present several symptoms that affect their quality
of life. Healthcare professionals should develop strategies to identify more properly these symptoms, especially sex-related and
psychological symptoms.
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1. INTRODUCTION
During the last decades, chronic diseases have supplanted
communicable diseases as the first cause of mortality and
morbidity in the population.[1] Chronic kidney disease
(CKD) is one of the chronic diseases that has grown rapidly,
most often in connection with the degradation of kidney func-
tion secondary to another chronic condition, such as diabetes
or hypertension[1] but also due to the ageing of the popula-
tion. According to the Global Burden of Disease Study,[2]
CKD ranked 18th on the list of causes of global deaths in
2010 (16.3 per 100,000 deaths annually) and has now be-
come a serious public health issue.[3] Moreover, patients
with CKD inevitably progress, over the medium to long term,
towards end-stage renal disease (ESRD), which necessitates
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long-term renal replacement therapy, the most common of
which is hemodialysis (HD).[4] Switzerland has not been
spared from the phenomenon: 350,000 of its inhabitants live
with the disease, 30,000 of which with a severe form of the
disease.[5] Consequently, CKD patients necessitating HD
treatment are on track the way to become a large vulnerable
population with complex healthcare needs.
Though extra-renal blood purification treatment such as HD
does prolong the life of ESRD patients, it carries numer-
ous constraints and can generate major complications.[6] In
this regard, authors[7–22] have pointed out that patients on
chronic HD experience a multitude of symptoms, both physi-
cal and psychological, owing primarily to the trajectory of
the kidney disease, to the different treatments received, and
to their side effects. In a review of the recent literature on the
topic, Almutary et al.[8] mentioned that the mean number of
symptoms per HD patient ranged from 6 to 20 across studies
and that the main symptoms reported by CKD patients, in-
cluding those on HD, were fatigue or lack of energy (81%),
feeling drowsy (75%), pain (65%), pruritus (61%) and dry
skin (57%). While the prevalence of physical symptoms is
considerable, HD patients also experience symptoms of a
psychological order, such as feeling sad, feeling irritable,
and feeling nervous.[7, 14, 17, 23] According to Humphreys et
al.,[24] any bothersome symptom not managed by the patient
or healthcare professionals can have negative repercussions
on patient health. Consequently, it is not surprising that
studies[7, 16, 17, 23] have found increased symptom burden to
be closely related to change in quality of life (QoL) among
HD patients and QoL to be a predictor of mortality in this
population.[25]
Ten years ago, Weisbord[23] bemoaned the scant research
geared to explore the prevalence and severity of self-
perceived symptoms among HD patients and to evaluate
their effect on QoL and depression. Almutary et al.[8] re-
iterated this point more recently, underscoring the need to
acquire a better understanding of symptom burden. In ad-
dition, Weisbord et al.[26] found there were cultural differ-
ences regarding prevalence and severity of self-perceived
symptoms among HD patients around the world. All of this
suggests that the symptomatology of HD patients should be
explored systematically in light of the cultural context in or-
der not only to enrich our understanding of this phenomenon
but also subsequently to propose tailored interventions. In
Switzerland, despite the growing number of HD patients, no
study has ever specifically explored the symptomatology of
this population. Furthermore, Almutary et al.[8] pointed out
that research on the subject often lacked a theoretical basis,
which constituted a shortcoming in terms of the choice of
variables investigated and the proposed relationship between
them. Against this background and drawing on Humphreys’
theory of symptom management,[24] we undertook a study
with a twofold objective: 1) to measure the prevalence and
severity of physical and emotional symptoms among HD
patients in Switzerland; and 2) to examine the relationship
between symptom prevalence and severity and patient QoL.
2. THEORETICAL FRAMEWORK
The UCSF School of Nursing Symptom Management
Model[24] provided the theoretical framework for the study.
Effective symptom management involves taking into consid-
eration three interrelated dimensions: symptom experience,
symptom management strategies, and outcomes. A symptom
was defined as a subjective experience reflecting a change in
state of health impacting well-being, especially among peo-
ple living with a chronic disease.[24] The notion of symptom
experience allowed researchers to identify the symptoms that
HD patients perceived and to determine their frequency and
severity. Humphreys et al.[24] specified that symptoms un-
supported by health professionals still had a major impact on
patients, their family and the healthcare system. According
to these researchers, this middle-range theory can help direct
research on symptom assessment, strategies used by people
to manage symptoms, and how symptoms affect their health
status. This theory is used to define the relationship between
the variables under study.
3. METHOD
3.1 Study design
A cross-sectional correlational design[27] was used to de-
scribe two dimensions of HD patient symptom experience —
prevalence and severity — and subsequently, to investigate
the relationship between symptom experience and patient
QoL.
3.2 Participants and setting
A convenience sample was recruited in five dialysis centers
in the Canton of Vaud (French-speaking part of Switzerland)
during routine weekday dialysis sessions. To be included
in the study, participants had to meet the following criteria:
1) age 18 years or older; 2) under active treatment for at
least six months; 3) fluent in written and spoken French; and
4) able to provide free and informed consent. Patients with
diagnosed dementia or in a critical condition were excluded,
as were people with a weak command of French. Patients
who consented to participate in the study completed a struc-
tured self-report questionnaire. A research assistant was on
site at the time to assist them, if needed (e.g., explain certain
questions or even read out all the items of the questionnaire).
The questionnaire took about 30 minutes to complete on
average and was collected at the end of the dialysis session.
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3.3 Measures
3.3.1 Sociodemographic and clinical data
Data were collected on sociodemographic dimensions, in-
cluding age, sex, marital status, employment situation, chil-
dren, and income, and on clinical concerns, including to-
bacco and alcohol use, years on dialysis and presence of
comorbid conditions. The clinical data were gathered from
hospital records. Also collected from the records were a
set of biological markers (albumin, hemoglobin, phosphate,
calcium, parathyroid hormone) and an indicator of dialysis
adequacy (kt/v). The core elements indicated by Boini et
al.[28] in their longitudinal study of QoL among 1,000 French
CKD patients were used as the basis of the questionnaire in
our study. This questionnaire had already been successfully
used in a past study of HD patients living in Switzerland.[29]
3.3.2 Symptoms
Prevalence and severity of physical and emotional symptoms
were assessed with the 30-item Dialysis Symptom Index
(DSI[30]). Respondents were asked to indicate whether they
experienced any of 30 symptoms in the past 7 days. Then, for
each patient, a symptom burden score ranging from 0 to 30
was calculated summing the reported symptoms scores.[31]
In addition, severity was measured for each reported symp-
tom following the procedure proposed by Weisbord.[30–32]
Specifically, patients were asked to rate each reported symp-
tom on a 5-point Likert scale from 1 (not at all bothersome)
to 5 (bothers very much). Symptoms not present were rated
0 in terms of severity.[31] Then, an overall symptom severity
score ranging from 0 to 150 was calculated by summing the
individual severity ratings.[31] The English version of the
DSI has been tested in different national contexts and has
obtained satisfactory scores on a number of psychometric
properties.[26, 30–32] For the purposes of our study, the DSI
was translated into French following the transcultural val-
idation method proposed by Vallerand.[33] Psychometrics
tests has demonstrated good psychometric properties of the
French version. The test-retest reliability method was used
and results showed a percent agreement of 61.9% to 95.2%,
with most of the symptoms (24/30) obtaining a percent agree-
ment equal to or greater than 80%. Average kappa statistics
was 0.53 (SD = 0.21), a value that is larger than the threshold
for moderate agreement, i.e. 0.4.[34] Finally, the items ob-
tained a Cronbach’s α of 0.83 regarding symptom prevalence
and of 0.89 regarding symptom severity. On the whole, the
tests indicated that the fidelity of the French version of the
DSI was more than satisfactory.[35]
3.3.3 Quality of life (QoL)
Patient self-perceived QoL was assessed with the French-
language version of the WHOQOL-BREF,[36] an abridged
version of the 100-item World Health Organization Quality
of Life instrument. The WHOQOL-BREF comprises 26
items, two of which serve to explore overall QoL and general
health. The other 24 items fall under four domains: physical
health (seven items), psychological state (six items), social
relationships (three items), and environmental conditions
(eight items). All were rated on a 5-point scale from 1 to 5,
with higher scores indicating better QoL. Then, raw scores
were normalized on a 0 – 100 scale. The WHOQOL-BREF
questionnaire has been shown to possess good discriminant
and content validity, as well as good test-retest reliability
and high internal consistency.[37] The French language trans-
lation was validated[36] on French-speaking patients with
neuromuscular disorders and has been proven to possess sat-
isfactory psychometric properties (Cronbach’s α > 0.65 for
each dimension and good acceptability by population with
less than 5% non-response). The instrument had already been
successfully used in a previous study with French-speaking
HD patients.[29]
3.4 Data analysis
First, quantitative variables were described using the fol-
lowing statistics: minimum, maximum, mean, standard de-
viation, median, and interquartile range (IQR). Qualitative
variables were described using frequency tables with counts
and percentages. Second, a set of Kruskal-Wallis tests was
run to describe differences in the distribution of symptom
prevalence and severity across sociodemographic and clinical
groups. Third, the Pearson correlation coefficient and multi-
variate linear regression analysis were used to examine the
relationship between symptom prevalence and severity, re-
spectively, and patient QoL (adjusting for sociodemographic,
clinical and biological characteristics). Finally, to compare
the distribution of symptom prevalence and severity found
in our study with similar metrics obtained for Italian and
American patients,[26] a set of t-tests and Fisher tests were
employed. The statistical significance level (p-value) was set
at 5% or less throughout. All statistical analyses were run
using the R-3.3.3 software package.
3.5 Ethical consideration
All HD patients were handed a document explaining the
purpose of the study and the procedures used to ensure
anonymity. Patients could refuse to participate and were free
to withdraw from the research at any time without prejudice
to their medical support. Those who agreed to participate
after sufficient reflection were asked to sign a consent form,
which was later forwarded to the researchers. The study was
approved by the Human Research Ethics Review Board of
the Canton of Vaud (Switzerland).
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Table 1. Sociodemographic and clinical characteristics of study patients
 
 
Sociodemographic, clinical and biological characteristics 
Study group (N = 119) 
Mean (SD) n % 
Age (in years) 67.1 (14.2)   
Sex       
 • Female  43 36.1 
 • Male  76 63.9 
Marital status      
 • Single  12 10.1 
 • Married  63 52.9 
 • Separated  18 15.1 
 • Widowed  21 17.6 
 • Living common law   5  4.2 
Employment status      
 • Active  15 12.6 
 • Inactive  31 26.1 
 • Retired  73 61.3 
Children (yes)  89 74.8 
Annual income (in CHF) (1 missing value)      
 • 32,579 or less  51 43.2 
 • 32,580 to 43,132  35 29.7 
 • 43,133 to 54,785  20 16.9 
 • 54,786 to 71,616   6  5.1 
 • 71,617 or more    6  5.1 
Months on hemodialysis 46.6 (51.3)   
Tobacco      
 • Former smoker  53 44.5 
 • Smoker  23 19.3 
 • Non-smoker  43 36.1 
Alcohol      
 • None  61 51.3 
 • Fewer than two standard units
*
 per day  55 46.2 
 • More than two standard units
*
 per day   3   2.5 
On transplant waiting list (1 missing value) 36 30.5 
Heart failure  38 31.9 
Hypertension  69 58.0 
Cardiac arrhythmia  25 21.0 
Diabetes (1 missing value)  47 39.8 
Peripheral vascular disease  11   9.2 
Chronic respiratory insufficiency  12 10.1 
Tumor   7   5.9 
Hepatitis   4   3.4 
Amputation   7   5.9 
Hemiplegia   2   1.7 
Blindness   8   6.7 
Albumin (g/dL, min–max: 35–52)
* 
       3.8 (0.7)   
Hemoglobin (g/dL, min–max: 12–16)
* 
     11.2 (1.3)   
Phosphate (mg/dL, min–max: 0.8–1.4)
*  
         1.3 (0.5)   
Calcium (mg/dL, min–max: 8.4 – 10.0)
*
       9.2 (0.8)   
Parathyroid hormone (pg/mL, min–max: 150–300)
*
 (1 missing value)   319.7 (280.1)   
kt/v (min–max: 0.94–2.29)
**
 (1 missing value)       1.6 (0.5)   
Note. * Norms of Vaud (Switzerland); ** According to KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney 
Disease (National Kidney Foundation, 2013) 
4. RESULTS
4.1 Sample characteristics
From January 2013 to September 2013, 119 HD patients
were enrolled in the study. Their sociodemographic charac-
teristics are shown in Table 1. Nearly two-thirds of partici-
pants were male and the mean age of sample was pretty high
(67 years). Three-quarters of the pooled sample had children
and slightly more than half was married. The vast majority
(87.4%) were retired or reported no gainful activity. This
explained the low income reported: about 90% earned less
than 54,785 CHF, well below the average annual income in
Switzerland of 85,740 CHF in 2013.[38] Nearly two-thirds of
the patients were smokers or former smokers and almost half
consumed alcohol. However, only 2.5% engaged in risky
drinking behaviors (more than two standard units per day)
based on the Canadian low-risk drinking guidelines[39] often
applied in Switzerland.[40] Patients had been on hemodialysis
for 47 months on average and 31% were on the transplant
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waiting list. Regarding medical history, the most present
comorbidities was hypertension, diabetes mellitus, and heart
failure. Mean values for all biological markers fell within the
non-problematic zone, except for hemoglobin, which was
slightly below the minimum level, and for parathyroid hor-
mone, which topped the maximum level but varied widely
across the sample.










Feeling tired or lack of energy 86 (72.3%) 3.4 (1.1) 
Dry skin 72 (60.5%) 3.1 (1.2) 
Trouble falling asleep 62 (52.1%) 3.6 (1.1) 
Muscle cramps    60 (50.4%) 3.2 (1.2) 
Trouble staying asleep 60 (50.4%) 3.4 (1.2) 
Decreased interest in sex 57 (47.9%) 4.1 (1.1) 
Dry mouth 56 (47.1%) 3.2 (1.3) 
Bone or joint pain 56 (47.1%) 3.3 (1.1) 
Itching 56 (47.1%) 3.1 (1.7) 
Difficulty becoming sexually aroused 54 (45.4%) 4.1 (1.1) 
Shortness of breath 50 (42.0%) 2.9 (1.0) 
Feeling anxious 45 (37.8%) 3.3 (1.1) 
Feeling nervous 43 (36.1%) 2.8 (1.1) 
Worrying 42 (35.3%) 3.3 (1.1) 
Numbness or tingling in feet 40 (33.6%) 2.8 (1.1) 
Difficulty concentrating 40 (33.6%) 2.7 (1.0) 
Muscle soreness 39 (32.8%) 2.8 (1.0) 
Feeling irritable 39 (32.8%) 2.7 (0.9) 
Decreased appetite 37 (31.1%) 2.9 (1.6) 
Cough 37 (31.1%) 2.7 (1.1) 
Feeling sad 36 (30.3%) 3.3 (1.3) 
Restless legs or difficulty keeping legs still 34 (28.6%) 3.0 (1.0) 
Constipation  30 (25.2%) 3.3 (1.4) 
Headache 30 (25.2%) 2.8 (1.0) 
Lightheadedness or dizziness 27 (22.7%) 2.7 (1.0) 
Swelling in legs 25 (21.0%) 2.8 (1.1) 
Diarrhea 21 (17.6%) 3.0 (1.1) 
Nausea 20 (16.8%) 3.1 (1.4) 
Vomiting 15 (12.6%) 2.8 (1.1) 
Chest pain 14 (11.8%) 3.0 (1.2) 







 Number of patients that reported symptom, percentage calculated on 
total (N = 119); 
**
 Based on a Likert scale from 1 “not at all bothersome” to 5 
“bothers very much…”; *** Median overall symptom severity score; Absence of 




For the 119 participants, the median number of symptoms
reported was 10 (IQR: 6–14). As shown in Table 2, five
symptoms were reported by at least 50% of the patients: feel-
ing tired or lack of energy, dry skin, trouble falling asleep,
trouble staying asleep, and muscle cramps. Regarding symp-
tom severity, two symptoms rated above 4 (high) and 13
rated 3 to 4 (moderate). The most severe symptoms were
the following: decreased interest in sex, difficulty becoming
sexually aroused, trouble falling asleep, feeling tired or lack
of energy, trouble staying asleep. The median global score
for symptom severity was 32 (IQR: 16.5–45.5). No sociode-
mographic characteristics or biological markers were related
to symptom prevalence or severity (p > .05). Where clinical
variables are concerned, hypertension, hepatitis, and periph-
eral vascular disease increased both prevalence and severity
of symptoms (respectively, p = .002 and p = .002, p = .041
and p = .013, p = .048 and p = .030). Presence of a tumor
increased symptom prevalence (p = .042) but not severity.
Surprisingly, being on the transplant waiting list was not
related to prevalence or severity of symptoms. Finally, a prin-
cipal component factor analysis of symptoms reported on the
French version of the DSI revealed no symptom cluster in
our sample.
Table 3. Regression models linking symptom prevalence
and severity, respectively, and QoL
 
 
  Overall β   Overall β   
QoL: Overall  
Symptom prevalence -1.76 * ---   
Symptom severity ---   -0.47 * 
QoL: Physical Health 
Symptom prevalence -1.63 * ---   
Symptom severity ---   -0.48 * 
QoL: Psychological State 
Symptom prevalence -0.97 * ---   
Symptom severity ---   -0.27 * 
QoL: Social Relationships 
Symptom prevalence -0.57 † ---   
Symptom severity ---   -0.17 * 
QoL: Environmental Conditions 
Symptom prevalence -0.36  ---   
Symptom severity ---   -0.08  
Note. Controls (for all models): variables listed in Table 1, height and 
weight (β values not shown); 
*
 p < .05; 
†
 marginally significant  
(p = .06) 
 
 
4.3 Correlation between symptoms and QoL
A significant negative Pearson correlation was observed be-
tween global scores for symptom prevalence and severity,
respectively, and patient QoL (-0.36 and -0.39, p < .001 in
both cases). Similar results were obtained for each of the
components of patients’ QoL (physical health, psychological
state, social relationships, and environmental conditions).
Pearson correlation coefficients ranged from -0.61 (physical
health and symptom severity) to -0.20 (environmental con-
ditions and symptom prevalence) and were all statistically
significant. To determine whether the results were robust to
the inclusion of confounding variables, ten regression mod-
els (see Table 3) were run to describe the net relationship
between variation in symptom prevalence and severity, re-
spectively, and QoL. The results of these models showed
that an increment in symptom prevalence was significantly
associated with a decrement in QoL. Considering a scale
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ranging from 0 to 100, where 0 represents the worst possible
QoL and 100 the best, the regression model showed decre-
ments ranging from 1.63 points for physical health to 0.36
for environmental conditions, and reaching 1.76 for overall
QoL. All the relationships were statistically significant ex-
cept for those regarding environmental conditions. As for
symptom severity, decrements ranged from 0.48 point for
physical health to 0.08 for environmental conditions, and
reached 0.47 for overall QoL. Again, all relationships were
statistically significant (p < .05) except for those regarding
environmental conditions.
5. DISCUSSION
Our results evidenced a high prevalence of physical and
psychological symptoms among HD patients living in the
French-speaking part of Switzerland. The patients in our
study reported an average of 10 symptoms, which is in line
with several other studies where the average number of symp-
toms reported ranged from 6 to 20.[8] More specifically, the
comparison with our results against those obtained by Weis-
bord et al.,[26] using identical instruments on Italian and
American HD patients, shows that the average number of
symptoms reported by Swiss patients was slightly greater
than the average number reported by American patients (9),
but less than the average number reported by Italian patients
(14). Even if the general levels are consistent and remain
high, context-related differences are evident and would need
further investigation. HD patients seem to experience more
symptoms than do people at an earlier stage of the illness
or with other pathologies, notably cancer.[14, 21] More specif-
ically, “feeling tired or lack of energy” was the most com-
monly reported symptom, reaching a prevalence of 72%.
Almutary et al.[8] found this symptom to be the most fre-
quently reported, with prevalence ranging from 49% to 92%
across studies. Similarly, Weisbord et al.[26] found analo-
gous results with a sample of Italian and American patients:
“feeling tired or lack of energy” affected 82% of the former
and 68% of the latter. Four other symptoms were reported
by more than 50% of our patients: dry skin (60.5%), trou-
ble falling asleep (52.1%), trouble staying asleep (50.4%),
and muscle cramps (50.4%). The strong presence of these
symptoms is in line with the findings reported by Weisbord
et al.[26] and Almutary et al.[8] However, the prevalence of
other symptoms differed in our study from the percentages
reported in the just quoted studies. In our comparison with
the results reported by Weisbord et al.,[26] the same pattern
emerged for 10 symptoms (bone or joint pain, worrying,
difficulty becoming sexually aroused, feeling sad, feeling
anxious, decreased interest in sex, feeling irritable, constipa-
tion, feeling nervous, difficulty concentrating), namely, the
highest prevalence was observed among Italian patients, the
lowest among American patients, and an intermediate level
among Swiss patients. Sex-related symptoms were promi-
nent. Indeed, 48% of our sample reported decreased interest
in sex and 45% reported increased difficulty becoming sex-
ually aroused. In the Weisbord et al.[26] study, fewer than
one-quarter of the American patients reported sex-related
issues, whereas these were the symptoms most reported by
the Italian patients (both at 82%). All these results suggest
that cultural context could be a key factor in the prevalence
of certain symptoms.
Regarding symptom severity, a simple comparison of symp-
tom severity showed substantial differences across the na-
tional patient groups. The average score for our patients was
32 (IQR: 16–45), greater than the scores reported by Weis-
bord et al.,[23, 26, 31] which reached 22 and 25. This difference
rested on the fact that 18 of 30 symptoms in our study scored
3 or higher (i.e., moderate severity), compared with only 12
and 14, respectively, for the two groups in the Weisbord et
al.[26] study. As was the case in Weisbord et al.[31] and in
Danquah et al.,[10] many of the most prevalent symptoms in
our study were also among the most severe, which might
explain the high average severity score we obtained. For
example, this was true for the severity of sleep issues, which
was in line with previous research that described them as
common among HD patients, strictly connected to HD treat-
ment and having a major impact on QoL.[41] Many of these
symptoms are undertreated, often owing to a general lack of
proper treatment for HD symptoms.[42] In particular, even
if pain represents a constant concern among health profes-
sionals, strategies to reduce pain in HD patients still seem
wanting.[42, 43] In part this is due to organizational uncer-
tainty about who, the nurse or the physician, is responsible
for treating symptoms.[44] Further to these results, health-
care professionals should assess presence of pain in HD
patients systematically and propose pharmacological and
non-pharmacological solutions to remedy the situation.
If we consider the findings on HD patient symptom preva-
lence and severity together, context emerges as a key factor.
Sex-related symptoms, in particular, follow a particular pat-
tern. Their prevalence is high in Italy, low in the United
States, and at an intermediate level in Switzerland. However,
unlike other symptoms that follow this pattern, their severity
is very high in all three contexts: 4.1 in Switzerland, 4.0 in
Italy, and 3.0–4.0 in the United States. This result is in line
with other studies that found sex-related symptoms to be a
major issue for HD patients[45] regardless of cultural differ-
ences.[46] Despite the solid literature on the subject, until
recently sex-related symptoms have remained in the shadows
because patients considered them part of the natural aging
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process[47] and healthcare professionals tended to underes-
timate them on account of their “non-lethal nature”.[47, 48]
Moreover, both healthcare professionals and patients are
at times embarrassed to talk about these issues[47] despite
the desire for information and, if needed, treatment. The
literature suggests that the taboo surrounding sexual prac-
tices, in general, and patient sexuality, in particular, are still
problematic issues for both healthcare professionals and re-
searchers. How HD facilities are organized may contribute
to maintain this taboo: they often have an open-space lay-
out that complicates communication between patients and
healthcare professionals or researchers. This may be why
Weisbord et al. have noted a clear reluctance among patients
to answer questions about sex-related matters[26] and why the
results reported by Coelho-Marques et al. are likely underes-
timated.[49] Generally speaking, it would not be unreasonable
to assume that a large part of the measures regarding sex-
related symptoms are underestimated. Given the above, many
researchers[45, 48, 50] have come out in favor of paying greater
attention to sex-related issues among HD patients, especially
women’s pathologies and non-pharmacological treatment,
two issues largely unexplored in this field of study.[50]
In addition to sex-related symptoms, a set of psychological
symptoms, including “worrying”, “feeling anxious”, “feeling
irritable”, “feeling nervous”, and “feeling sad”, rated high
among Italian patients, low among American patients, and in-
between among Swiss patients. This is true in terms of both
prevalence and severity, which further emphasizes the role
of context in this regard. Researchers have noted the impor-
tance of context empirically in the past but without detailing
what lies at the root of the differences.[26, 51, 52] The relevance
of context is described in Humphreys’ theory of symptom
management.[24, 53] Even if context is not at the center of the
theory, it can be broken down into three dimensions: cul-
tural, organizational, and structural.[24, 53] First, the cultural
dimension covers behavioral models and semantic nuances.
The influence of this dimension is interpreted from a con-
structivist perspective[54, 55] that considers every aspect of an
individual’s life as an experience to be interpreted in terms of
cultural models. From this perspective, illness and symptoms,
too, are experiences that are “socially constructed”[55] [p.70]
and that are influenced by social rules that prescribe how
to “live” and communicate the experience. Moreover, the
medical approach that identifies this change as a symptom is
more pervasive in some cultures than in others[56] and this in-
fluences how patients identify and, in turn, report symptoms.
These cultural differences are all the more pronounced when
it comes to psychological symptoms (e.g., worrying, feeling
anxious, feeling irritable), which are entirely self-reported.
Linguistic interactions, for their part, are not merely a means
for spreading cultural models, they add a further element of
differentiation. However rigorous the method used to trans-
late the original English scale, equivalent terms can have
small semantic nuances and connotations that impact how
symptoms are perceived and reported. Though the Italian
and French translations of the DSI scale are technically im-
peccable, semantic differences might remain and could have
influenced results. Second, the organizational dimension
refers to the fact that HD facilities are organized differently
in terms of both procedures and the healthcare professional
delivering treatment (i.e., dialysis technician in the United
States, nurse in Switzerland and Italy). These differences
can influence the easiness that patients feel relating to health-
care professionals and, consequently, the way they perceive
and report their symptoms. Third, the structural dimension
refers to differences across the national healthcare systems.
Rothgang et al.[57] developed a typology to classify these
systems based on who controls service regulation, funding,
and delivery. Accordingly, the Unites States is classified as
a private healthcare system[58] that rests on non-compulsory
private health insurance. Despite the high public cost of the
system,[59] funding is mainly indirect and the system is not
universally accessible. On the other hand, Italy is classified
as a system based on a national health insurance[58] funded
and regulated by the state and provided by both public and
private facilities. The system is universally accessible and
costs are state regulated. Switzerland is classified as a system
based on a social health insurance.[58] This system rests on
compulsory private insurance strictly regulated by public
authorities. Our results and those reported by Weisbord et
al.[26] suggest that the more a healthcare system is tax-based
or publicly funded, the less HD patients worry about the
cost of treatment and, consequently, the less likely they are
to minimize presence and severity of symptoms. Clearly,
further research is required in this regard in order to gain a
better grasp of the issue.
Also, our results show that patient QoL decreases systemati-
cally when symptoms worsen and even more so when new
symptoms appear. This relationship was weak, however, as
observed in previous research.[16, 60] We found that when an
existing symptom worsens, QoL decreases from 0.17 to 0.47
point on a scale of 0–100; when a new symptom appears,
QoL decreases 0.57 to 1.63 points. Despite the small size
of these effects, two factors suggest that the scores, though
numerically small, are not negligible. First, the average HD
patient has a burden of 10 symptoms that lowers overall QoL
on average by an amount between 14.6 points (based on
mean severity of 3.1 per symptom) or 17.6 points (based
on symptom prevalence) relative to a person with no symp-
toms. Second, studies[26, 61–64] suggest that decreased QoL is
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closely related to patient mortality. Consequently, systematic
evaluation of the symptom experience of HD patients seems
necessary in order to develop specific interventions aimed
at reducing symptom frequency and severity.[24] Finally, as
suggested by Almutary et al.,[8] studies of QoL among HD
patients should systematically include a measure of symptom
burden.
Our study presents certain limitations. First, the French ver-
sion of the DSI was used here for the first time. Despite a
positive preliminary validation, further testing seems neces-
sary in this regard. Second, patient symptom experience was
measured only in terms of prevalence and severity. Other di-
mensions might be considered in future, such as distress level
and frequency,[8] including in combination with prevalence
and severity.[10] Third, symptom experience is a longitudi-
nal dimension and may be subject to non-linear or lagged
effects.[65] Consequently, a cross-sectional study such as
ours might misrepresent the condition of patients owing to
the absence of time-sensitive measures. Fourth, depression
was not investigated in our study. Previous studies[7, 66–68]
have demonstrated the influence of depression on symptom
experience, particularly regarding psychological symptoms.
Fifth, patients not fluent in French were excluded from our
sample. Though linguistic and, by extension, cultural homo-
geneity facilitated the international comparison, this remains
a serious limitation of our study, given that Switzerland has
four official languages and a foreign contingent that con-
stitutes one-quarter of the total population (24.9% in 2016,
according to the Swiss Federal Statistical Office). Hence, the
generalizability of our findings is limited.
6. CONCLUSIONS
HD patients in Switzerland report a high number of symp-
toms often of moderate severity. Comparing our results with
international studies revealed that symptom prevalence and
severity vary widely across national contexts and seem to
be linked to cultural, linguistic and organizational factors.
Psychological and sex-related symptoms, in particular, need
to be further explored to uncover the causes behind the ob-
served variability. More generally, each symptom deserves
greater attention given that an increment in symptom pres-
ence or severity has a negative impact on patient QoL. Even
if individual symptoms have only a moderate impact, their
combined effect can have severe repercussions on QoL. Con-
sequently, it is imperative that the healthcare professionals
working with this population systematically evaluate the
symptoms of HD patients in order to propose tailored inter-
ventions aimed at reducing symptom frequency and severity
and, ultimately, at supporting the QoL of this vulnerable
population.
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